TS129918208	drug 25 48	nonclassical antifolate
TS69918208	drug 49 75	nolatrexed dihydrochloride
TS109918208	drug 169 195	nolatrexed dihydrochloride
TS119918208	drugEffect 372 387	bioavailability
TS99918208	drugEffect 592 607	bioavailability
TS89918208	mealTime 678 682	meal
TS19918208	drugEffect 893 908	bioavailability
TS149918208	sideeffect 988 998	toxicities
TS29918208	mealTime 1084 1105	After a standard meal
TS139918208	mealTime 1457 1463	fasted
TS49918208	food 1561 1565	food
TS79918208	drugEffect 1972 1987	Bioavailability
TS39918208	mealTime 2115 2136	after a standard meal
T1	drug 86 94	THYMITAQ
T2	drug 206 214	THYMITAQ
T3	modeadm 110 116	orally
T4	duration 117 127	for 5 days
T5	drug 221 264	nonclassical thymidylate synthase inhibitor
T6	modeadm 442 446	oral
T7	drug 447 457	nolatrexed
T8	numbers 478 497	Forty-five patients
T9	modeadm 516 520	oral
T10	drug 521 531	nolatrexed
T11	frequency 532 541	every 6 h
T12	duration 542 552	for 5 days
T13	dosage 565 580	288-1000 mg  m2
T14	frequency 582 585	day
T15	modeadm 615 619	oral
T16	drug 686 696	nolatrexed
T17	dosage 738 748	800 mg  m2
T18	frequency 750 753	day
T19	drug 756 766	Nolatrexed
T20	drug 847 857	Nolatrexed
T21	dosage 1066 1076	800 mg  m2
T22	frequency 1078 1081	day
T23	modeadm 1052 1056	oral
T24	drug 1124 1134	nolatrexed
T25	drug 1491 1501	nolatrexed
R1	no_effect_on_drug Arg1:TS49918208 Arg2:T25	
T26	drug 1583 1593	nolatrexed
T27	drug 1869 1879	Nolatrexed
T28	sideeffect 1660 1689;1814 1829	decrease in both thrombocytes and neutrophils
R2	has_sideeffect Arg1:T26 Arg2:T28	
T29	modeadm 1913 1917	oral
T30	dosage 1943 1953	800 mg  m2
T31	frequency 1955 1958	day
T32	duration 1959 1969	for 5 days
T33	drugEffect 2020 2054	inhibition of thymidylate synthase
T34	drug 2058 2068	nolatrexed
R3	has_effect Arg1:T34 Arg2:T33	
R4	slow_absorption Arg1:TS39918208 Arg2:T34	
